Search Results 31-40 of 974 for 씨밀레토토

  1. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    About this study. This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, ...

  2. https://www.mayoclinic.org/organization_concepts.xml

  3. Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be ...

  4. A Study to Collect Tissue, Fluids, Blood and/or Fungal Samples in Patients with Pulmonary and Extrapulmonary Coccidioidomycosis - Mayo Clinic

    The purpose of this study is to create a biorepository of tissue, fluid and fungal specimens for future studies. Participation eligibility. Participant ...

  5. Mayo Clinic

    Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR- ...

  6. https://www.mayoclinic.org/procedure_concepts.xml

  7. Cervical Health Awareness Month Archives - Mayo Clinic News Network

  8. A Study to Evaluate Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND) - Mayo Clinic

    About this study. The purpose of this study is to determine if patiromer treatment of subjects who developed hyperkalemia while receiving RAASi medications ...

  9. Joseph F. Drazkowski, M.D. - Mayo Clinic Faculty Profiles

    Mayo Clinic researcher Joseph F. Drazkowski, M.D., studies social determinants of health and quality of life issues for patients with epilepsy.

  10. Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: ...